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ABSTRACT 427 
Body fat distribution is a heritable risk factor for a range of adverse health consequences, 428 
including hyperlipidemia and type 2 diabetes. To identify protein-coding variants associated with body fat 429 
distribution, assessed by waist-to-hip ratio adjusted for body mass index, we analyzed 228,985 predicted 430 
coding and splice site variants available on exome arrays in up to 344,369 individuals from five major 431 
ancestries for discovery and 132,177 independent European-ancestry individuals for validation. We 432 
identified 15 common (minor allele frequency, MAF ≥ 5%) and 9 low frequency or rare (MAF < 5%) coding 433 
variants that have not been reported previously. Pathway/gene set enrichment analyses of all associated 434 
variants highlight lipid particle, adiponectin level, abnormal white adipose tissue physiology, and bone 435 
development and morphology as processes affecting fat distribution and body shape. Furthermore, the 436 
cross-trait associations and the analyses of variant and gene function highlight a strong connection to 437 
lipids, cardiovascular traits, and type 2 diabetes. In functional follow-up analyses, specifically in Drosophila 438 
RNAi-knockdown crosses, we observed a significant increase in the total body triglyceride levels for two 439 
genes (DNAH10 and PLXND1). By examining variants often poorly tagged or entirely missed by genome-440 
wide association studies, we implicate novel genes in fat distribution, stressing the importance of 441 
interrogating low-frequency and protein-coding variants. 442 
 443 
 444 
 445 
 446 
 447 
448 
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Body fat distribution, as assessed by waist-to-hip ratio (WHR), is a heritable trait and a well-449 
established risk factor for adverse metabolic outcomes1-6. A high WHR often indicates a large presence 450 
of intra-abdominal fat whereas a low WHR is correlated with a greater accumulation of gluteofemoral 451 
fat. Lower values of WHR have been consistently associated with lower risk of cardiometabolic diseases 452 
like type 2 diabetes (T2D)7,8, or differences in bone structure and gluteal muscle mass9. These 453 
epidemiological associations are consistent with the results of our previously reported genome-wide 454 
association study (GWAS) of 49 loci associated with WHR (after adjusting for body mass index, 455 
WHRadjBMI)10. Notably, a genetic predisposition to higher WHRadjBMI is associated with increased risk 456 
of T2D and coronary heart disease (CHD), and this association appears to be causal9. 457 
More recently, large-scale genetic studies have identified ~125 common loci for central obesity, 458 
primarily non-coding variants of relatively modest effect, for different measures of body fat distribution10-459 
16. Large scale interrogation of both common (minor allele frequency [MAF]≥5%) and low frequency or 460 
rare (MAF<5%) coding and splice site variation may lead to additional insights into the genetic and 461 
biological etiology of central obesity by narrowing in on causal genes contributing to trait variance. Thus, 462 
we set out to identify protein-coding and splice site variants associated with WHRadjBMI using exome 463 
array data and to explore their contribution to variation in WHRadjBMI through multiple follow-up 464 
analyses. 465 
RESULTS 466 
Protein-coding and splice site variation associated with body fat distribution 467 
We conducted a 2-stage fixed-effects meta-analysis testing both additive and recessive models in 468 
order to detect protein-coding genetic variants that influence WHRadjBMI (Online Methods, Figure 1). 469 
Our stage 1 meta-analysis included up to 228,985 variants (218,195 with MAF<5%) in up to 344,369 470 
individuals from 74 studies of European (N=288,492), South Asian (N=29,315), African (N=15,687), East 471 
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Asian (N=6,800) and Hispanic/Latino (N=4,075) descent, genotyped with an ExomeChip array 472 
(Supplementary Tables 1-3). For stage 2, we assessed 70 suggestively significant (P<2x10-6) variants from 473 
stage 1 in two independent cohorts from the United Kingdom [UK Biobank (UKBB), N=119,572] and 474 
Iceland (deCODE, N=12,605) (Online Methods, Supplementary Data 1-3) for a total stage 1+2 sample size 475 
of 476,546 (88% European). Variants were considered statistically significant in the total meta-analyzed 476 
sample (stage 1+2) when they achieved a significance threshold of P<2x10-7 after Bonferroni correction 477 
for multiple testing (0.05/246,328 variants tested). Of the 70 variants brought forward, two common and 478 
five rare variants were not available in either Stage 2 study (Tables 1-2, Supplementary Data 1-3). Thus, 479 
we require P<2x10-7 in Stage 1 for significance. Variants are considered novel if they were greater than 480 
one megabase (Mb) from a previously-identified WHRadjBMI lead SNP10-16.  481 
In stages 1 and 2 combined all ancestry meta-analyses, we identified 48 coding variants (16 novel) 482 
across 43 genes, 47 identified assuming an additive model, and one more variant under a recessive model 483 
(Table 1, Supplementary Figures 1-4). Due to the possible heterogeneity introduced by combining 484 
multiple ancestries17, we also performed a European-only meta-analysis. Here, four additional coding 485 
variants were significant (three novel) assuming an additive model (Table 1, Supplementary Figures 5-8). 486 
Of these 52 significant variants (48 from the all ancestry and 4 from the European-only analyses), eleven 487 
were of low frequency, including seven novel variants in RAPGEF3, FGFR2, R3HDML, HIST1H1T, PCNXL3, 488 
ACVR1C, and DARS2. These low frequency variants tended to display larger effect estimates than any of 489 
the previously reported common variants (Figure 2)10. In general, variants with MAF<1% had effect sizes 490 
approximately three times greater than those of common variants (MAF>5%). Although, we cannot rule 491 
out the possibility that additional rare variants with smaller effects sizes exist that, despite our ample 492 
sample size, we are still underpowered to detect (See estimated 80% power in Figure 2). However, in the 493 
absence of common variants with similarly large effects, our results point to the importance of 494 
investigating rare and low frequency variants to identify variants with large effects (Figure 2).  495 
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Given the established differences in the genetic underpinnings between sexes for 496 
WHRadjBMI10,11, we also performed sex-stratified analyses and report variants that were array-wide 497 
significant (P<2x10-7) in at least one sex stratum and exhibit significant sex-specific effects (Psexhet<7.14x10-498 
4, see Online Methods). We found four additional novel variants that were not identified in the sex-499 
combined meta-analyses (in UGGT2 and MMP14 for men only; and DSTYK and ANGPTL4 for women only) 500 
(Table 2, Supplementary Figures 9-15). Variants in UGGT2 and ANGPTL4 were of low frequency 501 
(MAFmen=0.6% and MAFwomen=1.9%, respectively). Additionally, 14 variants from the sex-combined meta-502 
analyses displayed stronger effects in women, including the novel, low frequency variant in ACVR1C 503 
(rs55920843, MAF=1.1%, Supplementary Figure 4). Overall, 19 of the 56 variants (32%) identified across 504 
all meta-analyses (48 from all ancestry, 4 from European-only and 4 from sex-stratified analyses) showed 505 
significant sex-specific effects on WHRadjBMI (Figure 1): 16 variants with significantly stronger effects in 506 
women, and three in men (Figure 1).  507 
In summary, we identified 56 array-wide significant coding variants (P<2.0x10-7); 43 common (14 508 
novel) and 13 low frequency or rare variants (9 novel). For all 55 significant variants from the additive 509 
model (47 from all ancestry, 4 from European-only, and 4 from sex-specific analyses), we examined 510 
potential collider bias18,19, i.e. potential bias in effect estimates caused by adjusting for a correlated and 511 
heritable covariate like BMI, for the relevant sex stratum and ancestry. We corrected each of the variant 512 
- WHRadjBMI associations for the correlation between WHR and BMI and the correlation between the 513 
variant and BMI  (Online Methods, Supplementary Table 7, Supplementary Note 1). Overall, 51 of the 55 514 
additive model variants were robust against collider bias18,19 across all primary and secondary meta-515 
analyses. Of the 55, 25 of the WHRadjBMI variants from the additive model were nominally associated 516 
with BMI (PBMI<0.05), yet effect sizes changed little after correction for potential biases (15% change in 517 
effect estimate on average). For 4 of the 55 SNPs (rs141845046, rs1034405, rs3617, rs9469913, Table 1), 518 
the association with WHRadjBMI appears to be attenuated following correction (Pcorrected> 9x10-4, 519 
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0.05/55), including one novel variant, rs1034405 in C3orf18. Thus, these 4 variants warrant further 520 
functional investigations to quantify their impact on WHR, as a true association may still exist, although 521 
the effect may be slightly overestimated in the current analysis. 522 
Using stage 1 meta-analysis results, we then aggregated low frequency variants across genes and 523 
tested their joint effect with both SKAT and burden tests20 (Supplementary Table 8, Online Methods). We 524 
identified five genes that reached array-wide significance (P<2.5x10-6, 0.05/16,222 genes tested), 525 
RAPGEF3, ACVR1C, ANGPTL4, DNAI1, and NOP2. However, while all genes analyzed included more than 526 
one variant, none remained significant after conditioning on the single variant with the most significant 527 
p-value. We identified variants within RAPGEF3, ACVR1C, ANGPTL4 that reached suggestive significance 528 
in Stage 1 and chip-wide significance in stage 1+2 for one or more meta-analyses (Tables 1 and 2); 529 
however, we did not identify any significant variants for DNAI1 and NOP2. While neither of these genes 530 
had a single variant that reached chip-wide significance, they each had variants with nearly significant 531 
results (NOP2: P=3.69x10-5, DNAI1: 4.64x10-5). Combined effects with these single variants and others in 532 
LD within the gene likely drove the association in our aggregate gene-based tests, but resulted in non-533 
significance following conditioning on the top variant. While our results suggest these associations are 534 
driven by a single variant, each gene may warrant consideration in future investigations. 535 
 536 
Conditional analyses 537 
 We next implemented conditional analyses to determine (1) the number of independent 538 
association signals the 56 array-wide significant coding variants represent, and (2) whether the 33 variants 539 
near known GWAS association signals (<+/- 1Mb) represent independent novel association signals. To 540 
determine if these variants were independent association signals, we used approximate joint conditional 541 
analyses to test for independence in stage 1 (Online Methods; Supplementary Table 4)20. Only the RSPO3-542 
KIAA0408 locus contains two independent variants 291 Kb apart, rs1892172 in RSPO3 (MAF=46.1%, 543 
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Pconditional=4.37x10-23 in the combined sexes, and Pconditional=2.4x10-20 in women) and rs139745911 in 544 
KIAA0408 (MAF=0.9%, Pconditional=3.68x10-11 in the combined sexes, and Pconditional=1.46x10-11 in women; 545 
Figure 3A).  546 
Further, 33 of our significant variants are within one Mb of previously identified GWAS tag SNPs 547 
for WHRadjBMI. We again used approximate joint conditional analysis to test for independence in the 548 
stage 1 meta-analysis dataset and obtained further complementary evidence from the UKBB dataset 549 
where necessary (Online Methods). We identified one coding variant representing a novel independent 550 
signal in a known locus [RREB1; stage1 meta-analysis, rs1334576, EAF = 0.44, Pconditional= 3.06x10-7, 551 
(Supplementary Table 5, Figure 3 [B]); UKBB analysis, rs1334576, RREB1, Pconditional= 1.24x10-8, 552 
(Supplementary Table 6) in the sex-combined analysis.  553 
In summary, we identified a total of 56 WHRadjBMI-associated coding variants in 41 independent 554 
association signals. Of these 41 independent association signals, 24 are new or independent of known 555 
GWAS-identified tag SNPs (either >1MB +/- or array-wide significant following conditional analyses) 556 
(Figure 1). Thus, bringing our total to 15 common and 9 low-frequency or rare novel variants following 557 
conditional analyses. The remaining non-GWAS-independent variants may assist in narrowing in on the 558 
causal variant or gene underlying these established association signals. 559 
Gene set and pathway enrichment analysis 560 
To determine if the significant coding variants highlight novel biological pathways and/or provide 561 
additional support for previously identified biological pathways, we applied two complementary pathway 562 
analysis methods using the EC-DEPICT (ExomeChip Data-driven Expression Prioritized Integration for 563 
Complex Traits) pathway analysis tool,21,22 and PASCAL23 (Online Methods). While for PASCAL all variants 564 
were used, in the case of EC-DEPICT, we examined 361 variants with suggestive significance (P<5x10-4)10,17 565 
from the combined ancestries and combined sexes analysis (which after clumping and filtering became 566 
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101 lead variants in 101 genes). We separately analyzed variants that exhibited significant sex-specific 567 
effects (Psexhet<5x10-4).  568 
The sex-combined analyses identified 49 significantly enriched gene sets (FDR<0.05) that grouped 569 
into 25 meta-gene sets (Supplementary Note 2, Supplementary Data 4-5). We noted a cluster of meta-570 
gene sets with direct relevance to metabolic aspects of obesity (“enhanced lipolysis,” “abnormal glucose 571 
homeostasis,” “increased circulating insulin level,” and “decreased susceptibility to diet-induced 572 
obesity”); we observed two significant adiponectin-related gene sets within these meta-gene sets. While 573 
these pathway groups had previously been identified in the GWAS DEPICT analysis (Figure 4), many of the 574 
individual gene sets within these meta-gene sets were not significant in the previous GWAS analysis, such 575 
as “insulin resistance,” “abnormal white adipose tissue physiology,” and “abnormal fat cell morphology” 576 
(Supplementary Data 4, Figure 4, Supplementary Figure 16a), but represent similar biological 577 
underpinnings implied by the shared meta-gene sets. Despite their overlap with the GWAS results, these 578 
analyses highlight novel genes that fall outside known GWAS loci, based on their strong contribution to 579 
the significantly enriched gene sets related to adipocyte and insulin biology (e.g. MLXIPL, ACVR1C, and 580 
ITIH5) (Figure 4).  581 
To focus on novel findings, we conducted pathway analyses after excluding variants from previous 582 
WHRadjBMI analyses10 (Supplemental Note 2). Seventy-five loci/genes were included in the EC-DEPICT 583 
analysis, and we identified 26 significantly enriched gene sets (13 meta-gene sets). Here, all but one gene 584 
set, “lipid particle size”, were related to skeletal biology. This result likely reflects an effect on the pelvic 585 
skeleton (hip circumference), shared signaling pathways between bone and fat (such as TGF-beta) and 586 
shared developmental origin24 (Supplementary Data 5, Supplementary Figure 16b). Many of these 587 
pathways were previously found to be significant in the GWAS DEPICT analysis; these findings provide a 588 
fully independent replication of their biological relevance for WHRadjBMI. 589 
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We used PASCAL (Online Methods) to further distinguish between enrichment based on coding-590 
only variant associations (this study) and regulatory-only variant associations (up to 20 kb upstream of the 591 
gene from a previous GIANT study10). For completeness, we also compared the coding pathways to those 592 
that could be identified in the total previous GWAS effort (using both coding and regulatory variants) by 593 
PASCAL. The analysis revealed 116 significantly enriched coding pathways (FDR<0.05; Supplementary 594 
Table 9). In contrast, a total of 158 gene sets were identified in the coding+regulatory analysis that 595 
included data from the previous GIANT waist GWAS study. Forty-two gene sets were enriched in both 596 
analyses. Thus, while we observed high concordance in the -log10 (p-values) between ExomeChip and 597 
GWAS gene set enrichment (Pearson's r (coding vs regulatory only) = 0.38, P<10-300; Pearson's r (coding vs 598 
coding+regulatory) = 0.51, P<10-300), there are gene sets that seem to be enriched specifically for variants 599 
in coding regions (e.g., decreased susceptibility to diet-induced obesity, abnormal skeletal morphology) 600 
or unique to variants in regulatory regions (e.g. transcriptional regulation of white adipocytes) 601 
(Supplementary Figure 17).  602 
The EC-DEPICT and PASCAL results showed a moderate but strongly significant correlation (for EC-603 
DEPICT and the PASCAL max statistic, r = .277 with p = 9.8x10-253; for EC-DEPICT and the PASCAL sum 604 
statistic, r = .287 with p = 5.42x10-272). Gene sets highlighted by both methods strongly implicated a role 605 
for pathways involved in skeletal biology, glucose homeostasis/insulin signaling, and adipocyte biology. 606 
Indeed, we are even more confident in the importance of this core overlapping group of pathways due to 607 
their discovery by both methods (Supplementary Figure 18). 608 
Cross-trait associations 609 
To assess the relevance of our identified variants with cardiometabolic, anthropometric, and 610 
reproductive traits, we conducted association lookups from existing ExomeChip studies of 15 traits 611 
(Supplementary Data 6, Supplementary Figure 19). Indeed, the clinical relevance of central adiposity is 612 
likely to be found in the cascade of impacts such variants have on downstream cardiometabolic 613 
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disease.22,25-29 We found that variants in STAB1 and PLCB3 display the greatest number of significant cross-614 
trait associations, each associating with seven different traits (P<9.8x10-4, 0.05/51 variants tested). Of 615 
note, these two genes cluster together with RSPO3, DNAH10, MNS1, COBLL1, CCDC92, and ITIH3 616 
(Supplementary Data 6, Supplementary Figure 19). The WHR-increasing alleles in this cluster of variants 617 
exhibit a pattern of increased cardiometabolic risk (e.g. increased fasting insulin [FI], two-hour glucose 618 
[TwoHGlu], and triglycerides [TG]; and decreased high-density lipoprotein cholesterol [HDL]), but also 619 
decreased BMI. This phenomenon, where variants associated with lower BMI are also associated with 620 
increased cardiometabolic risk, has been previously reported.30-36. A recent Mendelian Randomization 621 
(MR) analysis of the relationship between central adiposity (measured as WHRadjBMI) and 622 
cardiometabolic risk factors found central adiposity to be causal.9 Using 48 WHR-increasing variants 623 
reported in the recent GIANT analysis10 to calculate a polygenic risk score, Emdin et al. found that a 1 SD 624 
increase in genetic risk of central adiposity was associated with higher total cholesterol, triglyceride levels, 625 
fasting insulin and two-hour glucose, and lower HDL – all indicators of cardiometabolic disease, and also 626 
associated with a 1 unit decrease in BMI9.   627 
We conducted a search in the NHGRI-EBI GWAS Catalog37,38 to determine if any of our significant 628 
ExomeChip variants are in high LD (R2>0.7) with variants associated with traits or diseases not covered by 629 
our cross trait lookups (Supplementary Data 7). We identified several cardiometabolic traits (adiponectin, 630 
coronary heart disease etc.) and behavioral traits potentially related to obesity (carbohydrate, fat intake 631 
etc.) with GWAS associations that were not among those included in cross-trait analyses and nearby one 632 
or more of our WHRadjBMI- associated coding variants. Additionally, many of our ExomeChip variants are 633 
in LD with GWAS variants associated with other behavioral and neurological traits (schizophrenia, bipolar 634 
disorder etc.), and inflammatory or autoimmune diseases (Crohn’s Disease, multiple sclerosis etc.) 635 
(Supplementary Data 7).  636 
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Given the established correlation between total body fat percentage and WHR (R= 0.052 to 637 
0.483)39-41, we examined the association of our top exome variants with both total body fat percentage 638 
(BF%) and truncal fat percentage (TF%) available in a sub-sample of up to 118,160 participants of UKBB 639 
(Supplementary Tables 10-11). Seven of the common novel variants were significantly associated 640 
(P<0.001, 0.05/48 variants examined) with both BF% and TF% in the sexes-combined analysis (COBLL1, 641 
UHRF1BP1, WSCD2, CCDC92, IFI30, MPV17L2, IZUMO1). Only one of our tag SNPs, rs7607980 in COBLL1, 642 
is nearby a known total body fat percentageBF% GWAS locus (rs6738627; R2=0.1989, distance=6751 bp, 643 
with our tag SNP)42. Two additional variants, rs62266958 in EFCAB12 and rs224331 in GDF5, were 644 
significantly associated with TF% in the women-only analysis. Of the nine SNPs associated with at least 645 
one of these two traits, all variants displayed much greater magnitude of effect on TF% compared to BF% 646 
(Supplementary Figure 20).  647 
Previous studies have demonstrated the importance of examining common and rare variants 648 
within genes with mutations known to cause monogenic diseases43,44. We assessed enrichment of our 649 
WHRadjBMI within genes that cause monogenic forms of lipodystrophy) and/or insulin resistance 650 
(Supplementary Data 8). No significant enrichment was observed (Supplementary Figure 21). For 651 
lipodystrophy, the lack of significant findings may be due in part to the small number of implicated genes 652 
and the relatively small number of variants in monogenic disease-causing genes, reflecting their 653 
intolerance of variation.  654 
Genetic architecture of WHRadjBMI coding variants 655 
We used summary statistics from our stage 1 results to estimate the phenotypic variance 656 
explained by ExomeChip coding variants. We calculated the variance explained by subsets of SNPs across 657 
various significance thresholds (P< 2x10-7 to 0.2) and conservatively estimated using only independent tag 658 
SNPs (Supplementary Table 12, Online Methods, and Supplementary Figure 22). The 22 independent 659 
significant coding SNPs in stage 1 account for 0.28% of phenotypic variance in WHRadjBMI. For 660 
  
  30 
independent variants that reached suggestive significance in stage 1 (P<2x10-6), 33 SNPs explain 0.38% of 661 
the variation; however, the 1,786 independent SNPs with a liberal threshold of P<0.02 explain 13 times 662 
more variation (5.12%). While these large effect estimates may be subject to winner’s curse, for array-663 
wide significant variants, we detected a consistent relationship between effect magnitude and MAF in our 664 
stage 2 analyses in UK Biobank and deCODE (Supplementary Data 1-3). Notably, the Exomechip coding 665 
variants explained less of the phenotypic variance than in our previous GIANT investigation, wherein 49 666 
significant SNPs explained 1.4% of the variance in WHRadjBMI. When considering all coding variants on 667 
the ExomeChip in men and women together, 46 SNPs with a P<2x10-6 and 5,917 SNPs with a P<0.02 explain 668 
0.51% and 13.75% of the variance in WHRadjBMI, respectively. As expected given the design of the 669 
ExomeChip, the majority of the variance explained is attributable to rare and low frequency coding 670 
variants (independent SNPs with MAF<1% and MAF<5% explain 5.18% and 5.58%, respectively). However, 671 
for rare and low frequency variants, those that passed significance in stage 1 explain only 0.10% of the 672 
variance in WHRadjBMI. As in Figure 2, these results also indicate that there are additional coding variants 673 
associated with WHRadjBMI that remain to be discovered, particularly rare and low frequency variants 674 
with larger effects than common variants. Due to observed differences in association strength between 675 
women and men, we estimated variance explained for the same set of SNPs in women and men 676 
separately. As observed in previous studies10, there was significantly (PRsqDiff<0.002=0.05/21, Bonferroni-677 
corrected threshold) more variance explained in women compared to men at each significance threshold 678 
considered (differences ranged from 0.24% to 0.91%).  679 
To better understand the potential clinical impact of WHRadjBMI associated variants, we 680 
conducted penetrance analysis using the UKBB population (both sexes combined, and men- and women-681 
only). We compared the number of carriers and non-carriers of the minor allele for each of our significant 682 
variants in centrally obese and non-obese individuals to determine if there is a significant accumulation 683 
of the minor allele in either the centrally obese or non-obese groups (Online Methods). Three rare and 684 
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low frequency variants (MAF ≤ 1%) with larger effect sizes (effect size > 0.90) were included in the 685 
penetrance analysis using World Health Organization (WHO- obese women WHR>0.85 and obese men 686 
WHR>0.90) WHR cut-offs for central obesity. Of these, one SNV (rs55920843-ACVR1C; Psex-combined=9.25x10-687 
5; Pwomen=4.85x10-5) showed a statistically significant difference in the number of carriers and non-carriers 688 
of the minor allele when the two strata were compared (sex-combined obese carriers=2.2%; non-obese 689 
carriers=2.6%; women obese carriers=2.1%; non-obese women carriers=2.6% (Supplementary Table 13, 690 
Supplementary Figure 23). These differences were significant in women, but not in men (Pmen<5.5x10-3 691 
after Bonferroni correction for 9 tests) and agree with our overall meta-analysis results, where the minor 692 
allele (G) was significantly associated with lower WHRadjBMI in women only (Tables 1 and 2). 693 
Evidence for functional role of significant variants 694 
Drosophila Knockdown 695 
Considering the genetic evidence of adipose and insulin biology in determining body fat 696 
distribution10, and the lipid signature of the variants described here, we examined whole-body 697 
triglycerides levels in adult Drosophila, a model organism in which the fat body is an organ functionally 698 
analogous to mammalian liver and adipose tissue and triglycerides are the major source of fat storage45. 699 
Of the 51 genes harboring our 56 significantly associated variants, we identified 27 with Drosophila 700 
orthologues for functional follow-up analyses. In order to prioritize genes for follow-up, we selected genes 701 
with large changes in triglyceride storage levels (> 20% increase or > 40% decrease, as chance alone is 702 
unlikely to cause changes of this magnitude, although some decrease is expected) after considering each 703 
corresponding orthologue in an existing large-scale screen for adipose with ≤2 replicates per knockdown 704 
strain.45 Two orthologues, for PLXND1 and DNAH10, from two separate loci met these criteria. For these 705 
two genes, we conducted additional knockdown experiments with ≥5 replicates using tissue-specific 706 
drivers (fat body [cg-Gal4] and neuronal [elav-Gal4] specific RNAi-knockdowns) (Supplementary Table 707 
14). A significant (P<0.025, 0.05/2 orthologues) increase in the total body triglyceride levels was observed 708 
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in DNAH10 orthologue knockdown strains for both the fat body and neuronal drivers. However, only the 709 
neuronal driver knockdown for PLXND1 produced a significant change in triglyceride storage. DNAH10 710 
and PLXND1 both lie within previous GWAS identified regions. Adjacent genes have been highlighted as 711 
likely candidates for the DNAH10 association region, including CCDC92 and ZNF664 based on eQTL 712 
evidence. However, our fly knockdown results support DNAH10 as the causal genes underlying this 713 
association. Of note, rs11057353 in DNAH10 showed suggestive significance after conditioning on the 714 
known GWAS variants in nearby CCDC92 (sex-combined Pconditional=7.56x10-7; women-only rs11057353 715 
Pconditional= 5.86x10-7, Supplementary Table 6; thus providing some evidence of multiple causal 716 
variants/genes underlying this association signal. Further analyses are needed to determine whether the 717 
implicated coding variants from the current analysis are the putatively functional variants, specifically how 718 
these variants affect transcription in and around these loci, and exactly how those effects alter biology of 719 
relevant human metabolic tissues. 720 
eQTL Lookups  721 
To gain a better understanding of the potential functionality of novel and low frequency variants, 722 
we examined the cis-association of the identified variants with expression level of nearby genes in 723 
subcutaneous adipose tissue, visceral omental adipose tissue, skeletal muscle and pancreas from GTEx46, 724 
and assessed whether the exome and eQTL associations implicated the same signal (Online Methods, 725 
Supplementary Data 9, Supplementary Table 15). The lead exome variant was associated with expression 726 
level of the coding gene itself for DAGLB, MLXIPL, CCDC92, MAPKBP1, LRRC36 and UQCC1. However, at 727 
three of these loci (MLXIPL, MAPKBP1, and LRRC36), the lead exome variant is also associated with 728 
expression level of additional nearby genes, and at three additional loci, the lead exome variant is only 729 
associated with expression level of nearby genes (HEMK1 at C3orf18; NT5DC2, SMIM4 and TMEM110 at 730 
STAB1/ITIH3; and C6orf106 at UHRF1BP1). Although detected with a missense variant, these loci are also 731 
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consistent with a regulatory mechanism of effect as they are significantly associated with expression levels 732 
of genes, and the association signal may well be due to LD with nearby regulatory variants.  733 
Some of the coding genes implicated by eQTL analyses are known to be involved in adipocyte 734 
differentiation or insulin sensitivity: e. g. for MLXIPL, the encoded carbohydrate responsive element 735 
binding protein is a transcription factor, regulating glucose-mediated induction of de novo lipogenesis in 736 
adipose tissue, and expression of its beta-isoform in adipose tissue is positively correlated with adipose 737 
insulin sensitivity47,48. For CCDC92, the reduced adipocyte lipid accumulation upon knockdown confirmed 738 
the involvement of its encoded protein in adipose differentiation49.  739 
Biological Curation 740 
To gain further insight into the possible functional role of the identified variants, we conducted 741 
thorough searches of the literature and publicly available bioinformatics databases (Supplementary Data 742 
10-11, Box 1, Online Methods). Many of our novel low frequency variants are in genes that are intolerant 743 
of nonsynonymous mutations (e.g. ACVR1C, DARS2, FGFR2; ExAC Constraint Scores >0.5). Like previously 744 
identified GWAS variants, several of our novel coding variants lie within genes that are involved in glucose 745 
homeostasis (e.g. ACVR1C, UGGT2, ANGPTL4), angiogenesis (RASIP1), adipogenesis (RAPGEF3), and lipid 746 
biology (ANGPTL4, DAGLB) (Supplementary Data 10, Box 1).  747 
 748 
DISCUSSION  749 
Our two-staged approach to analysis of coding variants from ExomeChip data in up to 476,546 750 
individuals identified a total of 56 array-wide significant variants in 41 independent association signals, 751 
including 24 newly identified (23 novel and one independent of known GWAS signals) that influence 752 
WHRadjBMI. Nine of these variants were low frequency or rare, indicating an important role for low 753 
frequency variants in the polygenic architecture of fat distribution and providing further insights into its 754 
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underlying etiology. While, due to their rarity, these coding variants only explain a small proportion of the 755 
trait variance at a population level, they may, given their predicted role, be more functionally tractable 756 
than non-coding variants and have a critical impact at the individual and clinical level. For instance, the 757 
association between a low frequency variant (rs11209026; R381Q; MAF<5% in ExAC) located in the IL23R 758 
gene and multiple inflammatory diseases (such as psoriasis50, rheumatoid arthritis51, ankylosing 759 
spondylitis52, and inflammatory bowel diseases53) led to the development of new therapies, targeting IL23 760 
and IL12 in the same pathway (reviewed in 54-56). Thus, we are encouraged that our associated low 761 
frequency coding variants displayed large effect sizes; all but one of the nine novel low frequency variants 762 
had an effect size larger than the 49 SNPs reported in Shungin et al. 2015, and some of these effect sizes 763 
were up to 7-fold larger than those previously reported for GWAS. This finding mirrors results for other 764 
cardiometabolic traits57, and suggests variants of possible clinical significance with even larger effect and 765 
lower frequency variants will likely be detected through larger additional genome-wide scans of many 766 
more individuals. 767 
We continue to observe sexual dimorphism in the genetic architecture of WHRadjBMI11. Overall, 768 
we identified 19 coding variants that display significant sex differences, of which 16 (84%) display larger 769 
effects in women compared to men. Of the variants outside of GWAS loci, we reported three (two with 770 
MAF<5%) that show a significantly stronger effect in women and two (one with MAF<5%) that show a 771 
stronger effect in men. Additionally, genetic variants continue to explain a higher proportion of the 772 
phenotypic variation in body fat distribution in women compared to men10,11. Of the novel female (DSTYK 773 
and ANGPTL4) and male (UGGT2 and MMP14) specific signals, only ANGPTL4 implicated fat distribution 774 
related biology associated with both lipid biology and cardiovascular traits (Box 1). Sexual dimorphism in 775 
fat distribution is apparent from childhood and throughout adult life58-60, and at sexually dimorphic loci, 776 
hormones with different levels in men and women may interact with genomic and epigenomic factors to 777 
regulate gene activity, though this remains to be experimentally documented. Dissecting the underlying 778 
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molecular mechanisms of the sexual dimorphism in body fat distribution, and also how it is correlated 779 
with – and causing – important comorbidities like T2D and cardiovascular diseases will be crucial for 780 
improved understanding of disease risk and pathogenesis. 781 
Overall, we observe fewer significant associations between WHRadjBMI and coding variants on 782 
the ExomeChip than Turcot et al. 25 examining the association of low frequency and rare coding variants 783 
with BMI. In line with these observations, we identify fewer pathways and cross-trait associations. One 784 
reason for fewer WHRadjBMI implicated variants and pathways may be smaller sample size (NWHRadjBMI = 785 
476,546, NBMI = 718,639), and thus, lower statistical power. Power, however, is likely not the only 786 
contributing factor. For example, Turcot et al. 25 have comparative sample sizes between BMI and that of 787 
Marouli et al.22 studying height (Nheight = 711,428). However, greater than seven times the number of 788 
coding variants are identified for height than for BMI, indicating that perhaps a number of other factors, 789 
including trait architecture, heritability (possibly overestimated in some phenotypes), and phenotype 790 
precision, likely all contribute to our study’s capacity to identify low frequency and rare variants with large 791 
effects. Further, it is possible that the comparative lack of significant findings for WHRadjBMI and BMI 792 
compared to height may be a result of higher selective pressure against genetic predisposition to 793 
cardiometabolic phenotypes, such as BMI and WHR. As evolutionary theory predicts that harmful alleles 794 
will be low frequency61, we may need larger sample sizes to detect rare variants that have so far escaped 795 
selective pressures. Lastly, the ExomeChip is limited by the variants that are present on the chip, which 796 
was largely dictated by sequencing studies in European-ancestry populations and a MAF detection criteria 797 
of ~0.012%. It is likely that through an increased sample size, use of chips designed to detect variation 798 
across a range of continental ancestries, high quality, deep imputation with large reference samples (e.g. 799 
HRC), and/or alternative study designs, future studies will detect additional variation from the entire allele 800 
frequency spectrum that contributes to fat distribution phenotypes. 801 
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The collected genetic and epidemiologic evidence has now demonstrated that fat distribution (as 802 
measured by increased WHRadjBMI) is correlated with increased risk of T2D and CVD, and that this 803 
association is likely causal with potential mediation through blood pressure, triglyceride-rich lipoproteins, 804 
glucose, and insulin9. This observation yields an immediate follow-up question: Which mechanisms 805 
regulate depot-specific fat accumulation and are risks for disease, driven by increased visceral or 806 
decreased subcutaneous adipose tissue mass (or both)? Pathway analysis identified several novel 807 
pathways and gene sets related to metabolism and adipose regulation, bone growth and development 808 
we also observed a possible role for adiponectin, a hormone which has been linked to “healthy” expansion 809 
of adipose tissue and insulin sensitivity 62. Similarly, expression/eQTL results support the function and 810 
relevance of adipogenesis, adipocyte biology, and insulin signaling, supporting our previous findings for 811 
WHRadjBMI10. We also provide evidence suggesting known biological functions and pathways 812 
contributing to body fat distribution (e.g., diet-induced obesity, angiogenesis, bone growth and 813 
morphology, and enhanced lipolysis). 814 
The ultimate aim of genetic investigations of obesity-related traits, like those presented here, is 815 
to identify genomic pathways that are dysregulated leading to obesity pathogenesis, and may result in a 816 
myriad of downstream illnesses. Thus, our findings may enhance the understanding of central obesity and 817 
identify new molecular targets to avert its negative health consequences. Significant cross-trait 818 
associations and additional associations observed in the GWAS Catalog are consistent with expected 819 
direction of effect for several traits, i.e. the WHR-increasing allele is associated with higher values of TG, 820 
DBP, fasting insulin, TC, LDL and T2D across many significant variants. However, it is worth noting that 821 
there are some exceptions. For example, rs9469913-A in UHRF1BP1 is associated with both increased 822 
WHRadjBMI and increased HDL. Also, we identified two variants in MLXIPL (rs3812316 and rs35332062), 823 
a well-known lipids-associated locus, in which the WHRadjBMI-increasing allele also increases all lipid 824 
levels, risk for hypertriglyceridemia, SBP and DBP. However, our findings show a significant and negative 825 
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association with HbA1C, and nominally significant and negative associations with two-hour glucose, 826 
fasting glucose, and Type 2 diabetes, and potential negative associations with biomarkers for liver disease 827 
(e.g. gamma glutamyl transpeptidase). Other notable exceptions include ITIH3 (negatively associated with 828 
BMI, HbA1C, LDL and SBP), DAGLB (positively associated with HDL), and STAB1 (negatively associated with 829 
TC, LDL, and SBP in cross-trait associations). Therefore, caution in selecting pathways for therapeutic 830 
targets is warranted; one must look beyond the effects on central adiposity, but also at the potential 831 
cascading effects of related diseases. 832 
A seminal finding from this study is the importance of lipid metabolism for body fat distribution. 833 
In fact, pathway analyses that highlight enhanced lipolysis, cross-trait associations with circulating lipid 834 
levels, existing biological evidence from the literature, and knockdown experiments in Drosophila 835 
examining triglyceride storage point to novel candidate genes (ANGPTL4, ACVR1C, DAGLB, MGA, RASIP1, 836 
and IZUMO1) and new candidates in known regions (DNAH1010 and MLXIPL14) related to lipid biology and 837 
its role in fat storage. Newly implicated genes of interest include ACVR1C, MLXIPL, and ANGPTL4, all of 838 
which are involved in lipid homeostasis; all are excellent candidate genes for central adiposity. Carriers of 839 
inactivating mutations in ANGPTL4 (Angiopoietin Like 4), for example, display low triglyceride levels and 840 
low risk of coronary artery disease63. ACVR1C encodes the activin receptor-like kinase 7 protein (ALK7), a 841 
receptor for the transcription factor TGFB-1, well known for its central role in growth and development in 842 
general64-68, and adipocyte development in particular68. ACVR1C exhibits the highest expression in adipose 843 
tissue, but is also highly expressed in the brain69-71. In mice, decreased activity of ACVR1C upregulates 844 
PPARγ and C/EBPα pathways and increases lipolysis in adipocytes, thus decreasing weight and diabetes in 845 
mice69,72,73. Such activity is suggestive of a role for ALK7 in adipose tissue signaling and therefore for 846 
therapeutic targets for human obesity. MLXIPL, also important for lipid metabolism and postnatal cellular 847 
growth, is a transcription factor which activates triglyceride synthesis genes in a glucose-dependent 848 
manner74,75. The lead exome variant in this gene is highly conserved, most likely damaging, and is 849 
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associated with reduced MLXIPL expression in adipose tissue. Furthermore, in a recent longitudinal, in 850 
vitro transcriptome analysis of adipogenesis in human adipose-derived stromal cells, gene expression of 851 
MLXIPL was up-regulated during the maturation of adipocytes, suggesting a critical role in the regulation 852 
of adipocyte size and accumulation76. However, given our observations on cross-trait associations with 853 
variants in MLXIPL and diabetes-related traits, development of therapeutic targets must be approached 854 
cautiously.  855 
Taken together, our 24 novel variants for WHRadjBMI offer new biology, highlighting the 856 
importance of lipid metabolism in the genetic underpinnings of body fat distribution. We continue to 857 
demonstrate the critical role of adipocyte biology and insulin resistance for central obesity and offer 858 
support for potentially causal genes underlying previously identified fat distribution GWAS loci. Notably, 859 
our findings offer potential new therapeutic targets for intervention in the risks associated with abdominal 860 
fat accumulation, and represents a major advance in our understanding of the underlying biology and 861 
genetic architecture of central adiposity. 862 
 863 
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METHODS  1113 
Studies 1114 
Stage 1 consisted of 74 studies (12 case/control studies, 59 population-based studies, and five 1115 
family studies) comprising 344,369 adult individuals of the following ancestries: 1) European descent (N= 1116 
288,492), 2) African (N= 15,687), 3) South Asian (N= 29,315), 4) East Asian (N=6,800), and 5) Hispanic 1117 
(N=4,075). Stage 1 meta-analyses were carried out in each ancestry separately and in the all ancestries 1118 
group, for both sex-combined and sex-specific analyses. Follow-up analyses were undertaken in 132,177 1119 
individuals of European ancestry from the deCODE anthropometric study and UK Biobank (Supplementary 1120 
Tables 1-3). Conditional analyses were performed in the all ancestries and European descent groups. 1121 
Informed consent was obtained for participants by the parent study and protocols approved by each 1122 
study’s institutional review boards. 1123 
Phenotypes 1124 
For each study, WHR (waist circumference divided by hip circumference) was corrected for age, 1125 
BMI, and the genomic principal components (derived from GWAS data, the variants with MAF >1% on the 1126 
ExomeChip, and ancestry informative markers available on the ExomeChip), as well as any additional 1127 
study-specific covariates (e.g. recruiting center), in a linear regression model. For studies with non-related 1128 
individuals, residuals were calculated separately by sex, whereas for family-based studies sex was included 1129 
as a covariate in models with both men and women. Additionally, residuals for case/control studies were 1130 
calculated separately. Finally, residuals were inverse normal transformed and used as the outcome in 1131 
association analyses. Phenotype descriptives by study are shown in Supplementary Table 3. 1132 
Genotypes and QC 1133 
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The majority of studies followed a standardized protocol and performed genotype calling using 1134 
the algorithms indicated in Supplementary Table 2, which typically included zCall3. For 10 studies 1135 
participating in the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, 1136 
the raw intensity data for the samples from seven genotyping centers were assembled into a single project 1137 
for joint calling4. Study-specific quality control (QC) measures of the genotyped variants were 1138 
implemented before association analysis (Supplementary Tables 1-2). Furthermore, to assess the 1139 
possibility that any significant associations with rare and low-frequency variants could be due to allele 1140 
calling in the smaller studies, we performed a sensitivity meta-analysis including all large studies (>5,000 1141 
participants) and compared to all studies. We found very high concordance for effect sizes, suggesting 1142 
that smaller studies do not bias our results (Supplementary Fig. 24). 1143 
Study-level statistical analyses 1144 
Individual cohorts were analyzed for each ancestry separately, in sex-combined and sex-specific 1145 
groups, with either RAREMETALWORKER (http://genome.sph.umich.edu/wiki/RAREMETALWORKER) or 1146 
RVTESTs (http://zhanxw.github.io/rvtests/), to associate inverse normal transformed WHRadjBMI with 1147 
genotype accounting for cryptic relatedness (kinship matrix) in a linear mixed model. These software 1148 
programs are designed to perform score-statistic based rare-variant association analysis, can 1149 
accommodate both unrelated and related individuals, and provide single-variant results and variance-1150 
covariance matrices. The covariance matrix captures linkage disequilibrium (LD) relationships between 1151 
markers within 1 Mb, which is used for gene-level meta-analyses and conditional analyses77,78. Single-1152 
variant analyses were performed for both additive and recessive models.  1153 
Centralized quality-control 1154 
Individual cohorts identified ancestry population outliers based on 1000 Genome Project phase 1 1155 
ancestry reference populations. A centralized quality-control procedure implemented in EasyQC79 was 1156 
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applied to individual cohort association summary statistics to identify cohort-specific problems: (1) 1157 
assessment of possible errors in phenotype residual transformation; (2) comparison of allele frequency 1158 
alignment against 1000 Genomes Project phase 1 reference data to pinpoint any potential strand issues, 1159 
and (3) examination of quantile-quantile (QQ) plots per study to identify any inflation arising from 1160 
population stratification, cryptic relatedness and genotype biases.  1161 
Meta-analyses 1162 
Meta-analyses were carried out in parallel by two different analysts at two sites using 1163 
RAREMETAL77. During the meta-analyses, we excluded variants if they had call rate <95%, Hardy-Weinberg 1164 
equilibrium P-value <1x10-7, or large allele frequency deviations from reference populations (>0.6 for all 1165 
ancestries analyses and >0.3 for ancestry-specific population analyses). We also excluded from 1166 
downstream analyses markers not present on the Illumina ExomeChip array 1.0, variants on the Y-1167 
chromosome or the mitochondrial genome, indels, multiallelic variants, and problematic variants based 1168 
on the Blat-based sequence alignment analyses. Significance for single-variant analyses was defined at an 1169 
array-wide level (P<2x10-7). For all suggestive significant variants from Stage 1, we tested for significant 1170 
sex differences. We calculated Psexhet for each SNP, testing for difference between women-specific and 1171 
men-specific beta estimates and standard errors using EasyStrata11,80. Each SNP that reached 1172 
Psexhet<0.05/# of variants tested (70 variants brought forward from Stage 1, Psexhet<7.14x10-4) was 1173 
considered significant. Additionally, while each individual study was asked to perform association analyses 1174 
stratified by race/ethnicity, and adjust for population stratification, all study-specific summary statistics 1175 
were meta-analyzed together for our all ancestry meta-analyses. To investigate potential heterogeneity 1176 
across ancestries, we did examine ancestry-specific meta-analysis results for our top 70 variants from 1177 
stage 1, and found no evidence of significant across-ancestry heterogeneity observed for any of our top 1178 
variants (I2 values noted in Supplementary Data 1-3). 1179 
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For the gene-based analyses, we applied two sets of criteria to select variants with a MAF<5% 1180 
within each ancestry based on coding variant annotation from five prediction algorithms (PolyPhen2, 1181 
HumDiv and HumVar, LRT, MutationTaster, and SIFT)80,81. Our broad gene-based tests included nonsense, 1182 
stop-loss, splice site, and missense variants annotated as damaging by at least one algorithm mentioned 1183 
above. Our strict gene-based tests included only nonsense, stop-loss, splice site, and missense variants 1184 
annotated as damaging by all five algorithms. These analyses were performed using the sequence kernel 1185 
association test (SKAT) and variable threshold (VT) methods. Statistical significance for gene-based tests 1186 
was set at a Bonferroni-corrected threshold of P<2.5x10-6 (0.05/~20,000 genes). All gene-based tests were 1187 
performed in RAREMETAL77. 1188 
Genomic inflation 1189 
We observed a marked genomic inflation of the test statistics even after controlling for population 1190 
stratification (linear mixed model) arising mainly from common markers; λGC in the primary meta-analysis 1191 
(combined ancestries and combined sexes) was 1.06 and 1.37 for all and only common coding and splice 1192 
site markers considered herein, respectively (Supplementary Figures 3, 7 and 13, Supplementary Table 1193 
16). Such inflation is expected for a highly polygenic trait like WHRadjBMI, for studies using a non-random 1194 
set of variants across the genome, and is consistent with our very large sample size79,82,83. 1195 
Conditional analyses 1196 
The RAREMETAL R-package77 was used to identify independent WHRadjBMI association signals 1197 
across all ancestries and European meta-analysis results. RAREMETAL performs conditional analyses by 1198 
using covariance matrices to distinguish true signals from the shadows of adjacent significant variants in 1199 
LD. First, we identified the lead variants (P<2x10-7) based on a 1Mb window centered on the most 1200 
significantly associated variant. We then conditioned on the lead variants in RAREMETAL and kept new 1201 
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lead signals at P<2x10-7 for conditioning in a second round of analysis. The process was repeated until no 1202 
additional signal emerged below the pre-specified P-value threshold (P<2x10-7). 1203 
To test if the associations detected were independent of the previously published WHRadjBMI 1204 
variants 10,14,16, we performed conditional analyses in the stage 1 discovery set if the GWAS variant or its 1205 
proxy (r20.8) was present on the ExomeChip using RAREMETAL77. All variants identified in our meta-1206 
analysis and the previously published variants were also present in the UK Biobank dataset84. This dataset 1207 
was used as a replacement dataset if a good proxy was not present on the ExomeChip as well as a 1208 
replication dataset for the variants present on the ExomeChip. All conditional analyses in the UK Biobank 1209 
dataset were performed using SNPTEST85-87. The conditional analyses were carried out reciprocally, 1210 
conditioning on the ExomeChip variant and then the previously published variant. An association was 1211 
considered independent of the previously published association if there was a statistically significant 1212 
association detected prior to the conditional analysis (P<2x10-7) with both the exome chip variant and the 1213 
previously published variant, and the observed association with both or either of the variants disappeared 1214 
upon conditional analysis (P>0.05). A conditional p-value between 9x10-6 and 0.05 was considered 1215 
inconclusive. However, a conditional p-value < 9x10-6 was also considered suggestive. 1216 
 1217 
Stage 2 meta-analyses 1218 
In our Stage 2, we sought to validate a total of 70 variants from Stage 1 that met P<2x10-6 in two 1219 
independent studies, the UK Biobank (Release 184) and Iceland (deCODE), comprising 119,572 and 12,605 1220 
individuals, respectively (Supplementary Tables 1-3). The same QC and analytical methodology were used 1221 
for these studies. Genotyping, study descriptions and phenotype descriptives are provided in 1222 
Supplementary Tables 1-3. For the combined analysis of Stage 1 plus 2, we used the inverse-variance 1223 
weighted fixed effects meta-analysis method. Significant associations were defined as those nominally 1224 
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significant (P<0.05) in the Stage 2 study and for the combined meta-analysis (Stage 1 plus Stage 2) 1225 
significance was set at P<2x10-7 (0.05/~250,000 variants). 1226 
Pathway enrichment analyses: EC-DEPICT 1227 
We adapted DEPICT, a gene set enrichment analysis method for GWAS data, for use with the 1228 
ExomeChip (‘EC-DEPICT’); this method is also described in a companion manuscript22. DEPICT’s primary 1229 
innovation is the use of “reconstituted” gene sets, where many different types of gene sets (e.g. canonical 1230 
pathways, protein-protein interaction networks, and mouse phenotypes) were extended through the use 1231 
of large-scale microarray data (see Pers et al.21 for details). EC-DEPICT computes p-values based on 1232 
Swedish ExomeChip data (Malmö Diet and Cancer (MDC), All New Diabetics in Scania (ANDIS), and Scania 1233 
Diabetes Registry (SDR) cohorts, N=11,899) and, unlike DEPICT, takes as input only the genes directly 1234 
containing the significant (coding) variants rather than all genes within a specified amount of linkage 1235 
disequilibrium (see Supplementary Note 2). 1236 
Two analyses were performed for WHRadjBMI ExomeChip: one with all variants p<5x10-4 (49 1237 
significant gene sets in 25 meta-gene sets, FDR <0.05) and one with all variants > 1 Mb from known GWAS 1238 
loci 10 (26 significant gene sets in 13 meta-gene sets, FDR <0.05). Affinity propagation clustering88 was 1239 
used to group highly correlated gene sets into “meta-gene sets”; for each meta-gene set, the member 1240 
gene set with the best p-value was used as representative for purposes of visualization (see 1241 
Supplementary Note). DEPICT for ExomeChip was written using the Python programming language, and 1242 
the code can be found at https://github.com/RebeccaFine/obesity-ec-depict. 1243 
Pathway enrichment analyses: PASCAL 1244 
We also applied the PASCAL pathway analysis tool23 to exome-wide association summary statistics 1245 
from Stage 1 for all coding variants. The method derives gene-based scores (both SUM and MAX statistics) 1246 
and subsequently tests for over-representation of high gene scores in predefined biological pathways. We 1247 
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used standard pathway libraries from KEGG, REACTOME and BIOCARTA, and also added dichotomized (Z-1248 
score>3) reconstituted gene sets from DEPICT21. To accurately estimate SNP-by-SNP correlations even for 1249 
rare variants, we used the UK10K data (TwinsUK89 and ALSPAC90 studies , N=3781). In order to separate 1250 
the contribution of regulatory variants from the coding variants, we also applied PASCAL to association 1251 
summary statistics of only regulatory variants (20 kb upstream) and regulatory+coding variants from the 1252 
Shungin et al10 study. In this way, we could comment on what is gained by analyzing coding variants 1253 
available on ExomeChip arrays. We performed both MAX and SUM estimations for pathway enrichment. 1254 
MAX is more sensitive to genesets driven primarily by a single signal, while SUM is better when there are 1255 
multiple variant associations in the same gene.  1256 
Monogenic obesity enrichment analyses 1257 
We compiled two lists consisting of 31 genes with strong evidence that disruption causes 1258 
monogenic forms of insulin resistance or diabetes; and 8 genes with evidence that disruption causes 1259 
monogenic forms of lipodystrophy. To test for enrichment of association, we conducted simulations by 1260 
matching each gene with others based on gene length and number of variants tested, to create a matched 1261 
set of genes. We generated 1,000 matched gene sets from our data, and assessed how often the number 1262 
of variants exceeding set significance thresholds was greater than in our monogenic obesity gene set.  1263 
Variance explained 1264 
We estimated the phenotypic variance explained by the association signals in Stage 1 all 1265 
ancestries analyses for men, women, and combined sexes91. For each associated region, we pruned 1266 
subsets of SNPs within 500 kb, as this threshold was comparable with previous studies, of the SNPs with 1267 
the lowest P-value and used varying P value thresholds (ranging from 2x10-7 to 0.02) from the combined 1268 
sexes results. Additionally, we examined all variants and independent variants across a range of MAF 1269 
thresholds. The variance explained by each subset of SNPs in each strata was estimated by summing the 1270 
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variance explained by the individual top coding variants. For the comparison of variance explained 1271 
between men and women, we tested for the significance of the differences assuming that the weighted 1272 
sum of chi-squared distributed variables tend to a Gaussian distribution ensured by Lyapunov’s central 1273 
limit theorem.91,92 1274 
Cross-trait lookups 1275 
To carefully explore the relationship between WHRadjBMI and related cardiometabolic, 1276 
anthropometric, and reproductive traits, association results for the 51 WHRadjBMI coding SNPs were 1277 
requested from existing or on-going meta-analyses from 7 consortia, including ExomeChip data from 1278 
GIANT (BMI, height), Global Lipids Genetics Consortium Results (GLGC) (total cholesterol, triglycerides, 1279 
HDL-cholesterol, LDL-cholesterol), International Consortium for Blood Pressure (IBPC)93 (systolic and 1280 
diastolic blood pressure), Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) 1281 
(glycemic traits), and DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium (type 2 1282 
diabetes). ).22,25-29  For coronary artery disease, we accessed 1000 Genomes Project-imputed GWAS data 1283 
released by CARDIoGRAMplusC4D94 and for the ReproGen consortium (age at menarche and menopause) 1284 
we used a combination of ExomeChip and 1000 Genomes Project-Imputed GWAS data. Heatmaps were 1285 
generated in R v3.3.2 using gplots (https://CRAN.R-project.org/package=gplots). We used Euclidean 1286 
distance based on p-value and direction of effect and complete linkage clustering for the dendrograms. 1287 
GWAS Catalog Lookups 1288 
In order to determine if significant coding variants were associated with any related 1289 
cardiometabolic and anthropometric traits, we also searched the NHGRI-EBI GWAS Catalog for previous 1290 
variant-trait associations near our lead SNPs (+/- 500 kb). We used PLINK to calculate LD for variants using 1291 
ARIC study European participants. All SNVs within the specified regions with an r2 value > 0.7 were retained 1292 
from NHGRI-EBI GWAS Catalog for further evaluation37. Consistent direction of effect was based on WHR-1293 
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increasing allele, LD, and allele frequency. Therefore, when a GWAS Catalog variant was not identical or 1294 
in high LD (r2 > 0.9) with the WHR variant, and MAF >0.45, we do not comment on direction of effect. 1295 
Body-fat percentage associations 1296 
We performed body fat percent and truncal fat percent look-up of 48 of the 56 identified variants 1297 
(tables 1 and 2) that were available in the UK Biobank, Release 184, data (notably some of the rare variants 1298 
in table 1 and 2 were not available) to further characterize their effects on WHRadjBMI. Genome-wide 1299 
association analyses for body fat percent and truncal fat percent were carried out in the UK Biobank. Prior 1300 
to analysis, phenotype data were filtered to exclude pregnant or possibly pregnant women, individuals 1301 
with body mass index < 15, and without genetically confirmed European ancestry, resulting in a sample 1302 
size of 120,286. Estimated measures of body fat percent and truncal fat percent were obtained using the 1303 
Tanita BC418MA body composition analyzer (Tanita, Tokyo, Japan). Individuals were not required to fast 1304 
and did not follow any specific instructions prior to the bioimpedance measurements. SNPTEST was used 1305 
to perform the analyses based on residuals adjusted for age, 15 principle components, assessment center 1306 
and the genotyping chip85.  1307 
Collider bias 1308 
In order to evaluate SNPs for possible collider bias18, we used results from a recent association 1309 
analysis from GIANT on BMI25. For each significant SNP identified in our additive models, WHRadjBMI 1310 
associations were corrected for potential bias due to associations between each variant and BMI (See 1311 
Supplementary Note 1 for additional details). Variants were considered robust against collider bias if they 1312 
met Bonferroni-corrected significance following correction (Pcorrected<9.09x10-4, 0.05/55 variants 1313 
examined). 1314 
Drosophila RNAi knockdown experiments 1315 
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For each gene in which coding variants were associated with WHRadjBMI in the final combined 1316 
meta-analysis (P < 2×10-7), its corresponding Drosophila orthologues were identified in the Ensembl 1317 
ortholog database (www.ensembl.org), when available. Drosophila triglyceride content values were 1318 
mined from a publicly available genome-wide fat screen data set 45 to identify potential genes for follow-1319 
up knockdowns. Estimated values represent fractional changes in triglyceride content in adult male flies. 1320 
Data are from male progeny resulting from crosses of male UAS-RNAi flies from the Vienna Drosophila 1321 
Resource Center (VDRC) and Hsp70-GAL4; Tub-GAL8ts virgin females. Two-to-five-day-old males were 1322 
sorted into groups of 20 and subjected to two one-hour wet heatshocks four days apart. On the seventh 1323 
day, flies were picked in groups of eight, manually crushed and sonicated, and the lysates heat-inactivated 1324 
for 10 min in a thermocycler at 95 °C. Centrifuge-cleared supernatants were then used for triglyceride 1325 
(GPO Trinder, Sigma) and protein (Pierce) determination. Triglyceride values from these adult-induced 1326 
ubiquitous RNAi knockdown individuals were normalized to those obtained in parallel from non-1327 
heatshocked progeny from the very same crosses. The screen comprised one to three biological replicates. 1328 
We followed up each gene with a >0.2 increase or >0.4 decrease in triglyceride content.  1329 
Orthologues for two genes were brought forward for follow-up, DNAH10 and PLXND1. For both 1330 
genes, we generated adipose tissue (cg-Gal4) and neuronal (elav-Gal4) specific RNAi-knockdown crosses 1331 
to knockdown transcripts in a tissue specific manner, leveraging upstream activation sequence (UAS)-1332 
inducible short-hairpin knockdown lines, available through the VDRC (Vienna Drosophila Resource 1333 
Center). Specifically, elav-Gal4, which drives expression of the RNAi construct in post mitotic neurons 1334 
starting at embryonic stages all the way to adulthood, was used. Cg drives expression in the fat body and 1335 
hemocytes starting at embryonic stage 12, all the way to adulthood. We crossed male UAS-RNAi flies and 1336 
elav-GAL4 or CG-GAL4 virgin female flies. All fly experiments were carried out at 25°C. Five-to-seven-day-1337 
old males were sorted into groups of 20, weighed and homogenated in PBS with 0.05% Tween with Lysing 1338 
Matrix D in a beadshaker. The homogenate was heat-inactivated for 10 min in a thermocycler at 70°C. 1339 
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10μl of the homogenate was subsequently used in a triglyceride assay (Sigma, Serum Triglyceride 1340 
Determination Kit) which was carried out in duplicate according to protocol, with one alteration: the 1341 
samples were cleared of residual particulate debris by centrifugation before absorbance reading. 1342 
Resulting triglyceride values were normalized to fly weight and larval/population density. We used the 1343 
non-parametric Kruskall-Wallis test to compare wild type with knockdown lines. 1344 
Expression quantitative trait loci (eQTLs) analysis 1345 
We queried the significant variant (Exome coding SNPs)-gene pairs associated with eGenes across 1346 
five metabolically relevant tissues (skeletal muscle, subcutaneous adipose, visceral adipose, liver and 1347 
pancreas) with at least 70 samples in the GTEx database46. For each tissue, variants were selected based 1348 
on the following thresholds: the minor allele was observed in at least 10 samples, and the minor allele 1349 
frequency was ≥ 0.01. eGenes, genes with a significant eQTL, are defined on a false discovery rate (FDR)95 1350 
threshold of ≤0.05 of beta distribution-adjusted empirical p-value from FastQTL. Nominal p-values were 1351 
generated for each variant-gene pair by testing the alternative hypothesis that the slope of a linear 1352 
regression model between genotype and expression deviates from 0. To identify the list of all significant 1353 
variant-gene pairs associated with eGenes, a genome-wide empirical p-value threshold64, pt, was defined 1354 
as the empirical p-value of the gene closest to the 0.05 FDR threshold. pt was then used to calculate a 1355 
nominal p-value threshold for each gene based on the beta distribution model (from FastQTL) of the 1356 
minimum p-value distribution f(pmin) obtained from the permutations for the gene. For each gene, 1357 
variants with a nominal p-value below the gene-level threshold were considered significant and included 1358 
in the final list of variant-gene pairs64. For each eGene, we also listed the most significantly associated 1359 
variants (eSNP). Only these exome SNPs with r2 > 0.8 with eSNPs were considered for the biological 1360 
interpretation (Supplementary eQTL GTEx). 1361 
We also performed cis-eQTL analysis in 770 METSIM subcutaneous adipose tissue samples as 1362 
described in Civelek, et al.96 A false discovery rate (FDR) was calculated using all p-values from the cis-1363 
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eQTL detection in the q-value package in R. Variants associated with nearby genes at an FDR less than 1% 1364 
were considered to be significant (equivalent p-value < 2.46 × 10−4).  1365 
1366 
1367 
1368 
1369 
1370 
1371 
1372 
1373 
1374 
1375 
1376 
1377 
1378 
1379 
1380 
1381 
1382 
1383 
1384 
For loci with more than one microarray probeset of the same gene associated with the 
exome variant, we selected the probeset that provided the strongest LD r2 between the exome variant 
and the eSNP. In reciprocal conditional analysis, we conditioned on the lead exome variant by 
including it as a covariate in the cis-eQTL detection and reporting the p-value of the eSNP and vice 
versa. We considered the signals to be coincident if both the lead exome variant and the eSNP were no 
longer significant after conditioning on the other and the variants were in high pairwise LD (r2 > 0.80). 
For loci that also harbored reported GWAS variants, we performed reciprocal conditional analysis 
between the GWAS lead variant and the lead eSNP. For loci with more than one reported GWAS variant, 
the GWAS lead variant with the strongest LD r2 with the lead eSNP was reported. 
Penetrance analysis 
Phenotype and genotype data from the UK Biobank (UKBB) were used for the penetrance analysis. 
Three of 16 rare and low frequency variants (MAF ≤ 1%) detected in the final Stage 1 plus 2 meta-analysis 
were available in the UKBB and had relatively larger effect sizes (>0.90). The phenotype data for these 
three variants were stratified with respect to waist-to-hip ratio (WHR) using the World Health 
Organization (WHO) guidelines. These guidelines consider women and men with WHR greater than 0.85 
and 0.90 as obese, respectively. Genotype and allele counts were obtained for the available variants and 
these were used to calculate the number of carriers of the minor allele. The number of carriers for women, 
men and all combined was then compared between two strata (obese vs. non-obese) using a χ2 test. The 
significance threshold was determined by using a Bonferroni correction for the number of tests performed 
(0.05/9=5.5x10-3)).  1385 
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DATA AVAILABILITY  1386 
Summary statistics of all analyses are available at https://www.broadinstitute.org/collaboration/giant/. 1387 
  1388 
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BOXES 1389 
Box 1. Genes of biological interest harboring WHR-associated variants 
PLXND1- (3:129284818, rs2625973, known locus) The major allele of a common non-synonymous 
variant in Plexin D1 (L1412V, MAF=26.7%) is associated with increased WHRadjBMI (β (SE)= 0.0156 
(0.0024), P-value=9.16x10-11). PLXND1 is a semaphorin class 3 and 4 receptor gene, and therefore, is 
involved in cell to cell signaling and regulation of growth in development for a number of different cell 
and tissue types, including those in the cardiovascular system, skeleton, kidneys, and the central 
nervous system97-101. Mutations in this gene are associated with Moebius syndrome102-105, and 
persistent truncus arteriosus99,106. PLXND1 is involved in angiogenesis as part of the SEMA and VEGF 
signalling pathways107-110. PLXND1 was implicated in the development of T2D through its interaction 
with SEMA3E in mice. SEMA3E and PLXND1 are upregulated in adipose tissue in response to diet-
induced obesity, creating a cascade of adipose inflammation, insulin resistance, and diabetes 
mellitus101. PLXND1 is highly expressed in adipose (both subcutaneous and visceral) (GTeX). PLXND1 is 
highly intolerant of mutations and therefore highly conserved (Supplementary Data 10). Last, our lead 
variant is predicted as damaging or possibly damaging for all algorithms examined (SIFT, 
Polyphen2/HDIV, Polyphen2/HVAR, LRT, MutationTaster).  
 
ACVR1C– (2:158412701, rs55920843, novel locus) The major allele of a low frequency non-synonymous 
variant in activin A receptor type 1C (rs55920843, N150H, MAF=1.1%) is associated with increased 
WHRadjBMI (β (SE)= 0.0652 (0.0105), P-value= 4.81x10-10). ACVR1C, also called Activin receptor-like 
kinase 7 (ALK7), is a type I receptor for TGFB (Transforming Growth Factor, Beta-1), and is integral for 
the activation of SMAD transcription factors; therefore, ACVR1C plays an important role in cellular 
growth and differentiation64-68, including adipocytes68. Mouse Acvr1c decreases secretion of insulin and 
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is involved in lipid storage69,72,73,69,72,73,111. ACVR1C exhibits the highest expression in adipose tissue, but 
is also highly expressed in the brain (GTEx)69-71. Expression is associated with body fat, carbohydrate 
metabolism and lipids in both obese and lean individuals70. ACVR1C is moderately tolerant of mutations 
(EXaC Constraint Scores: synonymous= -0.86, nonsynonymous = 1.25, LoF = 0.04, Supplementary Data 
10). Last, our lead variant is predicted as damaging for two of five algorithms examined (LRT and 
MutationTaster). 
 
FGFR2– (10:123279643, rs138315382, novel locus) The minor allele of a rare synonymous variant in 
Fibroblast Growth Factor Receptor 2 (rs138315382, MAF=0.09%) is associated with increased 
WHRadjBMI (β (SE) = 0.258 (0.049), P-value= 1.38x10-07). The extracellular portion of the FGFR2 protein 
binds with fibroblast growth factors, influencing mitogenesis and differentiation. Mutations in this gene 
have been associated with many rare monogenic disorders, including skeletal deformities, 
craniosynostosis, eye abnormalities, and LADD syndrome, as well as several cancers including breast, 
lung, and gastric cancer. Methylation of FGFR2 is associated with high birth weight percentile112. FGFR2 
is tolerant of synonymous mutations, but highly intolerant of missense and loss-of-function mutations 
(ExAC Constraint scores: synonymous=-0.9, missense=2.74, LoF=1.0, Supplementary Data 10). Last, this 
variant is not predicted to be damaging based on any of the 5 algorithms tested. 
 
ANGPTL4 – (19:8429323, rs116843064, novel locus) The major allele of a nonsynonymous low 
frequency variant in Angiopoietin Like 4 (rs116843064, E40K, EAF=98.1%) is associated with increased 
WHRadjBMI (β (SE) = 0.064 (0.011) P-value= 1.20x10-09). ANGPTL4 encodes a glycosylated, secreted 
protein containing a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome 
proliferation activators and functions as a serum hormone that regulates glucose homeostasis, 
triglyceride metabolism113,114, and insulin sensitivity115. Angptl4-deficient mice have 
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hypotriglyceridemia and increased lipoprotein lipase (LPL) activity, while transgenic mice 
overexpressing Angplt4 in the liver have higher plasma triglyceride levels and decreased LPL activity116. 
The major allele of rs116843064 has been previously associated with increased risk of coronary heart 
disease and increased TG63. ANGPTL4 is moderately tolerant of mutations (ExAC constraint scores 
synonymous=1.18, missense=0.21, LoF=0.0, Supplementary Data 10). Last, our lead variant is predicted 
damaging for four of five algorithms (SIFT, Polyphen 2/HDIV, Polyphen2/HVAR, and MutationTaster). 
 
RREB1 – (6:7211818, rs1334576, novel association signal) The major allele of a common non-
synonymous variant in the Ras responsive element binding protein 1 (rs1334576, G195R, EAF=56%) is 
associated with increased WHRadjBMI (β (SE)=0.017 (0.002), P-value=3.9x10-15). This variant is 
independent of the previously reported GWAS signal in the RREB1 region (rs1294410; 6:673875210). 
The protein encoded by this gene is a zinc finger transcription factor that binds to RAS-responsive 
elements (RREs) of gene promoters. It has been shown that the calcitonin gene promoter contains an 
RRE and that the encoded protein binds there and increases expression of calcitonin, which may be 
involved in Ras/Raf-mediated cell differentiation117-119. The ras responsive transcription factor RREB1 is 
a candidate gene for type 2 diabetes associated end-stage kidney disease118. This variant is highly 
intolerant to loss of function (ExAC constraint score LoF = 1, Supplementary Data 10). 
 
DAGLB – (7:6449496, rs2303361, novel locus) The minor allele of a common non-synonymous variant 
(rs2303361, Q664R, MAF=22%) in DAGLB (Diacylglycerol lipase beta) is associated with increased 
WHRadjBMI (β (SE)= 0.0136 (0.0025), P-value=6.24x10-8). DAGLB is a diacylglycerol (DAG) lipase that 
catalyzes the hydrolysis of DAG to 2-arachidonoyl-glycerol, the most abundant endocannabinoid in 
tissues. In the brain, DAGL activity is required for axonal growth during development and for retrograde 
synaptic signaling at mature synapses (2-AG)120. The DAGLB variant, rs702485 (7:6449272, r2= 0.306 
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and D’=1 with rs2303361) has been previously associated with high-density lipoprotein cholesterol 
(HDL) previously. Pathway analysis indicate a role in the triglyceride lipase activity pathway 121. DAGLB 
is tolerant of synonymous mutations, but intolerant of missense and loss of function mutations (ExAC 
Constraint scores: synonymous=-0.76, missense=1.07, LoF=0.94, Supplementary Data 10). Last, this 
variant is not predicted to be damaging by any of the algorithms tested.  
 
MLXIPL (7:73012042, rs35332062 and 7:73020337, rs3812316, known locus) The major alleles of two 
common non-synonymous variants (A358V, MAF=12%; Q241H, MAF=12%) in MLXIPL (MLX interacting 
protein like) are associated with increased WHRadjBMI (β (SE)= 0.02 (0.0033), P-value=1.78x10-9; β 
(SE)= 0.0213 (0.0034), P-value=1.98x10-10). These variants are in strong linkage disequilibrium (r2=1.00, 
D’=1.00, 1000 Genomes CEU). This gene encodes a basic helix-loop-helix leucine zipper transcription 
factor of the Myc/Max/Mad superfamily. This protein forms a heterodimeric complex and binds and 
activates carbohydrate response element (ChoRE) motifs in the promoters of triglyceride synthesis 
genes in a glucose-dependent manner74,75. This gene is possibly involved in the growth hormone 
signaling pathway and lipid metabolism. The WHRadjBMI-associated variant rs3812316 in this gene has 
been associated with the risk of non-alcoholic fatty liver disease and coronary artery disease74,122,123. 
Furthermore, Williams-Beuren syndrome (an autosomal dominant disorder characterized by short 
stature, abnormal weight gain, various cardiovascular defects, and mental retardation) is caused by a 
deletion of about 26 genes from the long arm of chromosome 7 including MLXIPL. MLXIPL is generally 
intolerant to variation, and therefore conserved (ExAC Constraint scores: synonymous = 0.48, 
missense=1.16, LoF=0.68, Supplementary Data 10). Last, both variants reported here are predicted as 
possible or probably damaging by one of the algorithms tested (PolyPhen).  
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RAPGEF3 (12:48143315, rs145878042, novel locus) The major allele of a low frequency non-
synonymous variant in Rap Guanine-Nucleotide-Exchange Factor (GEF) 3 (rs145878042, L300P, 
MAF=1.1%) is associated with increased WHRadjBMI (β (SE)=0.085 (0.010), P-value = 7.15E-17). RAPGEF3 
codes for an intracellular cAMP sensor, also known as Epac (the Exchange Protein directly Activated by 
Cyclic AMP). Among its many known functions, RAPGEF3 regulates the ATP sensitivity of the KATP 
channel involved in insulin secretion124, may be important in regulating adipocyte differentiation125-127, 
plays an important role in regulating adiposity and energy balance128. RAPGEF3 is tolerant of mutations 
(ExAC Constraint Scores: synonymous = -0.47, nonsynonymous = 0.32, LoF = 0, Supplementary Data 
10). Last, our lead variant is predicted as damaging or possibly damaging for all five algorithms 
examined (SIFT, Polyphen2/HDIV, Polyphen2/HVAR, LRT, MutationTaster).  
 
TBX15 (1:119427467, rs61730011, known locus) The major allele of a low frequency non-synonymous 
variant in T-box 15 (rs61730011, M460R, MAF=4.3%) is associated with increased WHRadjBMI 
(β(SE)=0.041(0.005)). T-box 15 (TBX15) is a developmental transcription factor expressed in adipose 
tissue, but with higher expression in visceral adipose tissue than in subcutaneous adipose tissue, and is 
strongly downregulated in overweight and obese individuals129. TBX15 negatively controls depot-
specific adipocyte differentiation and function130 and regulates glycolytic myofiber identity and muscle 
metabolism131. TBX15 is moderately intolerant of mutations and therefore conserved (ExAC Constraint 
Scores: synonymous = 0.42, nonsynonymous = 0.65, LoF = 0.88, Supplementary Data 10). Last, our lead 
variant is predicted as damaging or possibly damaging for four of five algorithms (Polyphen2/HDIV, 
Polyphen2/HVAR, LRT, MutationTaster). 
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FIGURES 1676 
Figure 1. Summary of meta-analysis study design and workflow. Abbreviations: 1677 
EUR- European, AFR- African, SAS- South Asian, EAS- East Asian, and HIS- Hispanic/Latino ancestry. 1678 
Figure 2. Minor allele frequency compared to estimated effect. This scatter plot displays the relationship 1679 
between minor allele frequency (MAF) and the estimated effect (β) for each significant coding variant in 1680 
our meta-analyses. All novel WHRadjBMI variants are highlighted in orange, and variants identified only 1681 
in models that assume recessive inheritance are denoted by diamonds and only in sex-specific analyses 1682 
by triangles. Eighty percent power was calculated based on the total sample size in the Stage 1+2 meta-1683 
analysis and P=2x10-7. Estimated effects are shown in original units (cm/cm) calculated by using effect 1684 
sizes in standard deviation (SD) units times SD of WHR in the ARIC study (sexes combined=0.067, 1685 
men=0.052, women=0.080).  1686 
Figure 3. Regional association plots for known loci with novel coding signals. Point color reflects r2 1687 
calculated from the ARIC dataset. In a) there are two independent variants in RSPO3 and KIAA0408, as 1688 
shown by conditional analysis. In b) we have a variant in RREB1 that is independent of the GWAS variant 1689 
rs1294421. 1690 
Figure 4. Heat maps showing DEPICT gene set enrichment results. For any given square, the color indicates 1691 
how strongly the corresponding gene (shown on the x-axis) is predicted to belong to the reconstituted 1692 
gene set (y-axis). This value is based on the gene’s z-score for gene set inclusion in DEPICT’s reconstituted 1693 
gene sets, where red indicates a higher and blue a lower z-score. To visually reduce redundancy and 1694 
increase clarity, we chose one representative "meta-gene set" for each group of highly correlated gene 1695 
sets based on affinity propagation clustering (Online Methods, Supplementary Note 2). Heatmap 1696 
intensity and DEPICT P-values (see P-values in Supplementary Data 4-5) correspond to the most 1697 
significantly enriched gene set within the meta-gene set. Annotations for the genes indicate (1) the minor 1698 
  
  81 
allele frequency of the significant ExomeChip (EC) variant (shades of blue; if multiple variants, the lowest-1699 
frequency variant was kept), (2) whether the variant’s P-value reached array-wide significance (<2x10-7) 1700 
or suggestive significance (<5x10-4) (shades of purple), (3) whether the variant was novel, overlapping 1701 
“relaxed” GWAS signals from Shungin et al.10 (GWAS P<5x10-4), or overlapping “stringent” GWAS signals 1702 
(GWAS P<5x10-8) (shades of pink), and (4) whether the gene was included in the gene set enrichment 1703 
analysis or excluded by filters (shades of brown/orange) (Online Methods and Supplementary 1704 
Information). Annotations for the gene sets indicate if the meta-gene set was found significant (shades of 1705 
green; FDR <0.01, <0.05, or not significant) in the DEPICT analysis of GWAS results from Shungin et al. 1706 
 1707 
 1708 
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TABLES 1709 
Table 1. Association results for Combined Sexes. Association results based on an additive or recessive model for coding variants that met array-wide significance (P<2x10-07) in the sex-combined 1710 
meta-analyses. 1711 
Locus 
(+/-1Mb 
of a 
given 
variant) 
Chr:Position 
(GRCh37)b 
rsID EA OA Genec 
Amino Acid 
Changec 
If locus is 
known, 
nearby (< 1 
MB) published 
variant(s) d 
N EAF βe SE P-value 
P-value for 
Sex-
heterogeneityf 
Other 
Criteria 
For Sigh 
Variants in Novel Loci 
All Ancestry Additive model Sex-combined analyses 
1 2:158412701 rs55920843 T G ACVR1C N150H - 455,526 0.989 0.065 0.011 4.8E-10 1.7E-07  
2 3:50597092 rs1034405 G A C3orf18 A162V - 455,424 0.135 0.016 0.003 1.9E-07 8.8E-01 G,C 
3 4:120528327 rs3733526 G A PDE5A A41V - 461,521 0.187 0.015 0.003 2.6E-08 5.2E-03  
4 6:26108117 rs146860658 T C HIST1H1T A69T - 217,995 0.001 0.229 0.042 4.3E-08 6.3E-01 S 
5 7:6449496 rs2303361 C T DAGLB Q664R - 475,748 0.221 0.014 0.003 6.2E-08 3.4E-03 G 
6 10:123279643 rs138315382 T C FGFR2 synonymous - 236,962 0.001 0.258 0.049 1.4E-07 1.1E-01 G,S 
7 11:65403651 rs7114037 C A PCNXL3 H1822Q - 448,861 0.954 0.029 0.005 1.8E-08 4.4E-01  
8 12:48143315 rs145878042 A G RAPGEF3 L300P - 470,513 0.990 0.085 0.010 7.2E-17 7.3E-03  
9 12:108618630 rs3764002 C T WSCD2 T266I - 474,637 0.737 0.014 0.002 9.8E-10 5.5E-01  
10 15:42032383 rs17677991 G C MGA P1523A - 469,874 0.345 0.015 0.002 3.5E-11 9.1E-01  
11 
16:4432029 rs3810818 A C VASN E384A - 424,163 0.231 0.016 0.003 2.0E-09 3.3E-01  
16:4445327 rs3747579 C T CORO7 R193Q - 453,078 0.299 0.018 0.002 2.2E-13 4.3E-02  
16:4484396 rs1139653 A T DNAJA3 N75Y - 434,331 0.284 0.015 0.002 4.3E-10 1.4E-01  
12 
19:49232226 rs2287922 A G RASIP1 R601C - 430,272 0.494 0.014 0.002 1.6E-09 3.7E-02  
19:49244220 rs2307019 G A IZUMO1 A333V - 476,147 0.558 0.012 0.002 4.7E-08 3.9E-02  
13 20:42965811 rs144098855 T C R3HDML P5L - 428,768 0.001 0.172 0.032 9.7E-08 1.0E+00 G 
  
  2 
European Ancestry Additive model Sex-combined analyses 
14 1:173802608 rs35515638 G A DARS2 K196R - 352,646 0.001 0.201 0.038 1.4E-07 6.0E-02 G 
15 14:58838668 rs1051860 A G ARID4A synonymous - 367,079 0.411 0.013 0.002 2.2E-08 1.3E-01  
16 15:42115747 rs3959569 C G MAPKBP1 R1240H - 253,703 0.349 0.017 0.003 2.0E-08 6.3E-01   
Variants in Previously Identified Loci 
All Ancestry Additive model Sex-combined analyses 
1 
1:119427467 rs61730011 A C 
TBX15 
M566R 
rs2645294, 
rs12731372, 
rs12143789, 
rs1106529 
441,461 0.957 0.041 0.005 2.2E-14 6.7E-01  
1:119469188 rs10494217 T G H156N 472,259 0.174 0.018 0.003 1.4E-10 6.0E-01  
2 1:154987704 rs141845046 C T ZBTB7B P190S rs905938 476,440 0.976 0.037 0.007 3.8E-08 7.9E-07 C 
3 2:165551201 rs7607980 T C COBLL1 N941D 
rs1128249, 
rs10195252, 
rs12692737, 
rs12692738, 
rs17185198 
389,883 0.879 0.026 0.004 1.6E-13 3.0E-30  
4 2:188343497 rs7586970 T C TFPI N221S rs1569135 452,638 0.697 0.016 0.002 3.0E-12 6.3E-01  
5 
3:52558008 rs13303 T C STAB1 M113T 
rs2276824 
470,111 0.445 0.019 0.002 5.5E-18 6.7E-02  
3:52833805 rs3617 C A ITIH3 Q315K 452,150 0.541 0.015 0.002 1.6E-12 4.0E-01 C 
6 
3:129137188 rs62266958 C T EFCAB12 R197H 
rs10804591 
476,382 0.936 0.036 0.004 8.3E-17 9.3E-05  
3:129284818 rs2625973 A C PLXND1 L1412V 476,338 0.733 0.016 0.002 9.2E-11 1.6E-05  
7 
4:89625427 rs1804080 G C HERC3 E946Q 
rs9991328 
446,080 0.838 0.021 0.003 1.5E-12 4.1E-06  
4:89668859 rs7657817 C T FAM13A V443I 476,383 0.815 0.016 0.003 5.0E-09 9.6E-05  
8 5:176516631 rs1966265 A G FGFR4 V10I rs6556301 455,246 0.236 0.023 0.003 1.7E-19 2.1E-01  
9 6:7211818 rs1334576g G A RREB1 G195R rs1294410 451,044 0.565 0.017 0.002 3.9E-15 1.5E-01  
10 6:34827085 rs9469913 A T UHRF1BP1 Q984H rs1776897 309,684 0.847 0.021 0.004 1.2E-08 2.7E-01 C 
11 
6:127476516 rs1892172 A G RSPO3 synonymous rs11961815, 
rs72959041, 
rs1936805 
476,358 0.543 0.031 0.002 2.6E-47 7.7E-09  
6:127767954 rs139745911g A G KIAA0408 P504S 391,469 0.010 0.103 0.012 6.8E-19 2.0E-04  
12 
7:73012042 rs35332062 G A 
MLXIPL 
A358V 
rs6976930 
451,158 0.880 0.020 0.003 1.8E-09 1.5E-01  
7:73020337 rs3812316 C G Q241H 454,738 0.881 0.021 0.003 2.0E-10 5.8E-02  
  
  3 
13 10:95931087 rs17417407 T G PLCE1 R240L rs10786152 476,475 0.173 0.018 0.003 2.5E-11 5.9E-01  
14 11:64031241 rs35169799 T C PLCB3 S778L rs11231693 476,457 0.061 0.034 0.004 9.1E-15 1.3E-04  
15 
12:123444507 rs58843120 G T ABDB9 F92L 
rs4765219, 
rs863750 
466,498 0.987 0.053 0.009 1.3E-08 3.5E-01  
12:124265687 rs11057353 T C 
DNAH10 
S228P 476,360 0.373 0.018 0.002 2.1E-16 2.7E-08  
12:124330311 rs34934281 C T T1785M 476,395 0.889 0.025 0.003 2.9E-14 3.1E-08  
12:124427306 rs11057401 T A CCDC92 S53C 467,649 0.695 0.029 0.002 7.3E-37 5.5E-11  
16 15:56756285 rs1715919 G T MNS1 Q55P rs8030605 476,274 0.096 0.023 0.004 8.8E-11 2.7E-02  
17 
16:67397580 rs9922085 G C 
LRRC36 
R101P 
rs6499129 
469,474 0.938 0.034 0.005 3.8E-13 5.9E-01  
16:67409180 rs8052655 G A G388S 474,035 0.939 0.034 0.005 5.5E-13 4.0E-01  
18 
19:18285944 rs11554159 A G IFI30  R76Q 
rs12608504 
476,389 0.257 0.015 0.002 3.5E-10 3.1E-03  
19:18304700 rs874628 G A MPV17L2 M72V 476,388 0.271 0.015 0.002 1.2E-10 2.5E-03  
19 
20:33971914 rs4911494 T C UQCC1 R51Q 
rs224333 
451,064 0.602 0.018 0.002 2.5E-16 1.5E-03  
20:34022387 rs224331 A C GDF5 S276A 345,805 0.644 0.017 0.003 1.8E-11 3.2E-03  
All Ancestry Recessive model Sex-combined analyses 
20 17:17425631 rs897453 C T PEMT V58L rs4646404 476,546 0.569 0.025 0.004 4.1E-11 8.2E-01  
European Ancestry Additive model Sex-combined analyses 
6 3:129293256 rs2255703 T C PLXND1 M870V rs10804591 420,520 0.620 0.014 0.002 3.1E-09 1.6E-04   
Abbreviations: GRCh37=human genome assembly build37;rsID=based on dbSNP; VEP=Ensembl Variant Effect Predictor toolset; GTEx=Genotype-Tissue Expression project;SD=standard deviation; SE=standard error;N=sample size; 1712 
EAF=effect allele frequency; EA=effect allele; OA=other allele.  1713 
a Coding variants refer to variants located in the exons and splicing junction regions.          1714 
b Variant positions are reported according to Human assembly build 37 and their alleles are coded based on the positive strand.  1715 
c The gene the variant falls in and amino acid change from the most abundant coding transcript is shown (protein annotation is based on VEP toolset and transcript abundance from GTEx database).  1716 
d Previously published variants within +/-1Mb are from Shungin et al.10, except for rs6976930 and rs10786152 from Graff et al.14 and rs6499129 from Ng. et al 16. 1717 
e Effect size is based on standard deviation (SD) per effect allele  1718 
f P-value for sex heterogeneity, testing for difference between women-specific and men-specific beta estimates and standard errors, was calculated using  EasyStrata: Winkler, T.W. et al. EasyStrata: evaluation and visualization of 1719 
stratified genome-wide association meta-analysis data. Bioinformatics 2015: 31, 259-61.PMID: 25260699. Bolded P-values met significance threshold after bonferonni correction (P-value<7.14E-04; i.e. 0.05/70 variants).  1720 
g rs1334576 in RREB1 is a new signal in a known locus that is independent from the known signal, rs1294410; rs139745911 in KIAA0408 is a new signal in a known locus that is independent from all known signals rs11961815, rs72959041, 1721 
rs1936805, in a known locus (see Supplementary 8A/B). 1722 
  
  4 
h Each flag indicates a that a secondary criteria for significance may not be met, G- P-value > 5x10-8 (GWAS significant), C- Association Signal was not robust against collider bias; S- variant was not available in stage 2 studies for validation 1723 
of Stage 1 association.             1724 
1725 
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Table 2. Association results for Sex-stratified analyses. Association results based on an additive or recessive model for coding variants that met array-wide significance (P<2x10-07) in the sex-1726 
specific meta-analyses and reach bonferonni corrected P-value for sex hetergeneity (Psexhet<7.14E-04). 1727 
Locus (+/-1Mb 
of a given 
variant) 
Chr:Position 
(GRCh37)c 
rsID EA OA Gened 
Amino Acid 
Changed 
In sex-
combined 
analysese 
If locus is known, nearby (< 
1 MB) published variant(s) 
f 
P-value for Sex-
heterogeneityg 
Men Women 
Other 
Criteria For 
Sigj 
N EAF βh SE P N EAF βh SE P 
Variants in Novel Loci 
All Ancestry Additive model Men only analyses 
1 13:96665697 rs148108950 A G UGGT2 P175L No - 1.5E-06 203,009 0.006 0.130 0.024 6.1E-08 221,390 0.004 -0.044 0.027 1.1E-01 G 
2 14:23312594 rs1042704 A G MMP14 D273N No - 2.6E-04 226,646 0.202 0.021 0.004 2.6E-08 250,018 0.197 0.002 0.004 6.1E-01   
All Ancestry Additive model Women only analyses 
3 1:205130413 rs3851294 G A DSTYK C641R No - 9.8E-08 225,803 0.914 -0.005 0.005 3.4E-01 249,471 0.912 0.034 0.005 4.5E-11   
4 2:158412701 rs55920843 T G ACVR1C N150H Yes - 1.7E-07 210,071 0.989 0.006 0.015 7.2E-01 245,808 0.989 0.113 0.014 1.7E-15   
5 19:8429323 rs116843064 G A ANGPTL4 E40K No - 1.3E-07 203,098 0.981 -0.017 0.011 1.4E-01 243,351 0.981 0.064 0.011 1.2E-09   
Variants in Previously Identified Loci 
All Ancestry Additive model Women only analyses 
1 1:154987704 rs141845046 C T ZBTB7B P190S Yes rs905938 7.9E-07 226,709 0.975 0.004 0.010 6.9E-01 250,084 0.977 0.070 0.010 2.3E-13   
2 2:165551201 rs7607980 T C COBLL1 N941D Yes 
rs1128249, rs10195252, 
rs12692737, rs12692738, 
rs17185198 
3.0E-30 173,600 0.880 -0.018 0.005 5.8E-04 216,636 0.878 0.062 0.005 6.7E-39   
3 
3:129137188 rs62266958 C T EFCAB12 R197H Yes 
rs10804591 
9.3E-05 226,690 0.937 0.018 0.006 3.1E-03 250,045 0.936 0.051 0.006 8.1E-18   
3:129284818 rs2625973 A C 
 PLXND1 
L1412V Yes 1.6E-05 226,650 0.736 0.005 0.003 1.9E-01 250,023 0.730 0.025 0.003 8.2E-14   
3:129293256 rs2255703 T C M870V Yes 5.0E-04 226,681 0.609 0.003 0.003 3.1E-01 250,069 0.602 0.018 0.003 1.9E-09   
4 4:89625427 rs1804080 G C HERC3 E946Q Yes rs9991328 4.1E-06 222,556 0.839 0.008 0.004 6.6E-02 223,877 0.837 0.034 0.004 2.1E-16   
  
  6 
4:89668859 rs7657817 C T FAM13A V443I Yes 9.6E-05 226,680 0.816 0.006 0.004 1.5E-01 242,970 0.815 0.026 0.004 5.9E-12   
5 
6:127476516 rs1892172 A G RSPO3 synonymous Yes rs11961815, rs72959041, 
rs1936805 
7.7E-09 226,677 0.541 0.018 0.003 5.6E-10 250,034 0.545 0.042 0.003 3.4E-48   
6:127767954 rs139745911i A G KIAA0408 P504S Yes 2.0E-04 188,079 0.010 0.057 0.017 6.8E-04 205,203 0.010 0.143 0.016 5.9E-19   
6 11:64031241 rs35169799 T C PLCB3 S778L Yes rs11231693 1.3E-04 226,713 0.061 0.016 0.006 9.6E-03 250,097 0.061 0.049 0.006 6.7E-16   
7 
12:124265687 rs11057353 T C 
DNAH10 
S228P Yes 
rs4765219, rs863750 
2.7E-08 226,659 0.370 0.005 0.003 8.3E-02 250,054 0.376 0.029 0.003 3.1E-22   
12:124330311 rs34934281 C T T1785M Yes 3.1E-08 226,682 0.891 0.006 0.005 1.9E-01 250,066 0.887 0.043 0.005 1.4E-20   
12:124427306 rs11057401 T A CCDC92 S53C Yes 5.5E-11 223,324 0.701 0.013 0.003 4.3E-05 244,678 0.689 0.043 0.003 1.0E-41   
Abbreviations: GRCh37=human genome assembly build 37;rsID=based on dbSNP; VEP=Ensembl Variant Effect Predictor toolset; GTEx=Genotype-Tissue Expression project; SD=standard deviation; SE=standard error;N=sample size; EA=effect 1728 
allele; OA=other allele; EAF=effect allele frequency. 1729 
a Coding variants refer to variants located in the exons and splicing junction regions.  1730 
b Bonferonni corrected Pvalue for the number of SNPs tested for sex-heterogeneity is <7.14E-04 i.e. 0.05/70 variants. 1731 
c Variant positions are reported according to Human assembly build 37 and their alleles are coded based on the positive strand.  1732 
d The gene the variant falls in and amino acid change from the most abundant coding transcript is shown (protein annotation is based on VEP toolset and transcript abundance from GTEx database). 1733 
e Variant was also identified as array-wide significant in the sex-combined analyses.             1734 
f Previously published variants within +/-1Mb are from Shungin D et al. New genetic loci link adipose and insulin biology to body fat distribution. Nature 2015; 518, 187–196 doi:10.1038/nature14132 (PMID 25673412). 1735 
g P-value for sex heterogeneity, testing for difference between women-specific and men-specific beta estimates and standard errors, was calculated using EasyStrata: Winkler, T.W. et al. EasyStrata: evaluation and visualization of stratified 1736 
genome-wide association meta-analysis data. Bioinformatics 2015: 31, 259-61. PMID: 25260699. 1737 
h Effect size is based on standard deviation (SD) per effect allele 1738 
i rs139745911 in KIAA0408 is a new signal in a known locus that is independent from all known signals rs11961815, rs72959041, rs1936805, in a known locus (see Supplementary 8A/B).  1739 
j Each flag indicates a that a secondary criteria for significance may not be met, G- P-value > 5x10-8 (GWAS significant), C- Association Signal was not robust against collider bias; S- variant was not availabel in Stage 2 studies for validation 1740 
of Stage 1 association. 1741 
 1742 
